Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization

Link to article at PubMed

Neurol Sci. 2020 Nov 13:1-4. doi: 10.1007/s10072-020-04887-4. Online ahead of print.


BACKGROUND: COVID-19 patients present with delirium during their hospitalization.

AIMS: To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors.

METHODS: COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales.

RESULTS: Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006).

DISCUSSION: The use of LMWH was associated with absence of delirium, independently of comorbidities and age.

CONCLUSIONS: The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae.

PMID:33185785 | PMC:PMC7664586 | DOI:10.1007/s10072-020-04887-4

Leave a Reply

Your email address will not be published.